Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.
Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A. Wysocki J, et al. Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3. Vaccine. 2017. PMID: 28262330 Free article. Clinical Trial.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.
Gadzinowski J, Tansey SP, Wysocki J, Kopińska E, Majda-Stanisławska E, Czajka H, Korbal P, Pietrzyk JJ, Baker SA, Giardina PC, Gruber WC, Emini EA, Scott DA. Gadzinowski J, et al. Pediatr Infect Dis J. 2015 Feb;34(2):180-5. doi: 10.1097/INF.0000000000000511. Pediatr Infect Dis J. 2015. PMID: 25126854 Clinical Trial.
Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
Pietrzyk JJ, Wysocki J, Pejcz J, Galaj A, Majda-Stanislawska E, Käyhty H, Thierry-Carstensen B, Jensen AM. Pietrzyk JJ, et al. Vaccine. 2008 Sep 26;26(41):5296-303. doi: 10.1016/j.vaccine.2008.07.033. Epub 2008 Aug 27. Vaccine. 2008. PMID: 18675870 Clinical Trial.
13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.
Martinón-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawska E, Omeñaca F, Bernaola Iturbe E, Blazquez Gamero D, Concheiro-Guisán A, Gimenez-Sanchez F, Szenborn L, Giardina PC, Patterson S, Gruber WC, Scott DA, Gurtman A. Martinón-Torres F, et al. Pediatrics. 2015 Apr;135(4):e876-86. doi: 10.1542/peds.2014-2941. Epub 2015 Mar 16. Pediatrics. 2015. PMID: 25780077 Clinical Trial.
Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.
Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, Omeñaca F, Concheiro-Guisan A, Gimenez-Sanchez F, Szenborn L, Blázquez-Gamero D, Moreno-Galarraga L, Giardina PC, Sun G, Gruber WC, Scott DA, Gurtman A. Martinón-Torres F, et al. Pediatr Infect Dis J. 2017 Mar;36(3):326-332. doi: 10.1097/INF.0000000000001428. Pediatr Infect Dis J. 2017. PMID: 27902652
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.
Vesikari T, Brzostek J, Ahonen A, Paassilta M, Majda-Stanislawska E, Szenborn L, Virta M, Clifford R, Jackowska T, Kimmel M, Bindi I, Keshavan P, Pedotti P, Toneatto D. Vesikari T, et al. Among authors: majda stanislawska e. Hum Vaccin Immunother. 2021 Nov 2;17(11):4689-4700. doi: 10.1080/21645515.2021.1968214. Epub 2021 Sep 28. Hum Vaccin Immunother. 2021. PMID: 34582323 Free PMC article. Clinical Trial.
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines.
Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislawska E, Gatchalian S, Fanic A, Dieussaert I, Schuerman L. Bermal N, et al. Pediatr Infect Dis J. 2011 Jan;30(1):69-72. doi: 10.1097/INF.0b013e3181f2da06. Pediatr Infect Dis J. 2011. PMID: 20980933 Clinical Trial.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Walter EB, et al. N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9. N Engl J Med. 2022. PMID: 34752019 Free PMC article.
43 results